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The carcinoembryonic antigen- related cell adhesion mol-
ecule (CEACAM) family comprises a group of heavily 
glycosylated molecules characterized by extracellular 
domains with immunoglobulin- related structures [1]. 
Carcinoembryonic antigen- related cell adhesion molecule 
1 (CEACAM1), also known as CD66a or biliary 
glycoprotein- 1, is commonly expressed in various tumor 
cell types [1]. A number of splice variants of CEACAM1 
are described in the human [2]. These variants differ 
with respect to the number of extracellular domains or 
type of intracellular cytoplasmic domains. In the case of 
the extracellular domains, they consist of one amino- 
terminal immunoglobulin variable- region- like (IgV- like) 
domain and a maximum of three immunoglobulin 
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Abstract
Carcinoembryonic antigen- related cell adhesion molecule 1 (CEACAM1) is ex-
pressed in a number of tumor cell types. The immunoreceptor tyrosine- based 
inhibitory motif (ITIM)- containing isoforms of this molecule which possess a 
long cytoplasmic tail (CEACAM1- L) generally play inhibitory roles in cell func-
tion by interacting with Src homology 2 domain- containing tyrosine phosphatase 
(SHP)- 1 and/or SHP- 2. Src family kinases (SFKs) are also known to bind to 
and phosphorylate CEACAM1- L isoforms. Here, we report that CEACAM1 was 
uniquely expressed at high levels in both human neoplastic mast cells (masto-
cytosis) and medullary thyroid carcinoma cell (MTC) lines, when compared 
with their expression in nonneoplastic mast cells or nonneoplastic C cells. This 
expression was mainly derived from CEACAM1- L isoforms based upon assess-
ment of CEACAM1 mRNA expression. CEACAM1 knockdown upregulated cell 
growth of HMC1.2 cells harboring KIT mutations detected in clinical masto-
cytosis, whereas downregulated the growth of TT cells harboring RET mutations 
detected in clinical MTCs. Immunoblotting, ELISA and immunoprecipitaion 
analysis showed that activated SHP- 1 is preferentially associated with CEACAM1 
in HMC1.2 cells harboring KIT mutations, whereas Src family kinases (SFKs) 
are preferentially associated with CEACAM1 in TT cells harboring RET muta-
tions. These studies suggest that the dominantly interacting proteins SHP1 or 
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constant- region- type- 2- like (IgC2- like) domains. In the 
case of the cytoplasmic domains, these various isoforms 
are connected via splicing to either a long cytoplasmic 
tail (L) containing two immunoreceptor tyrosine- based 
inhibitory motifs (ITIMs) or a short cytoplasmic tail (S) 
that lacks ITIMs. The IgV- like domains mediate hemo-
philic or heterophilic interactions [3, 4], whereas the roles 
of the varying number of IgC2- like domains remain 
unclear. The intracellular ITIMs coordinate inhibitory 
signaling by recruiting Src homology 2 domain- containing 
tyrosine phosphatase (SHP)- 1 or SHP- 2 following phos-
phorylation by Src family tyrosine kinases [5]. SHP- 1 
and SHP- 2 are nonreceptor tyrosine phosphatases, which 
inhibit signaling by reversing critical tyrosine phospho-
rylation reactions induced by the action of tyrosine kinases 
[6]. Thus, the ITIM- containing family members of 
CEACAM1 (CEACAM1- L) mediate negative signals, 
whereas ITIM- deficient CEACAM1 (CEACAM1- S) iso-
forms do not [1]. An increased ratio of CEACAM1- L / 
CEACAM1- S has been reported to be associated with 
decreased proliferation of tumor cells [7]. In addition 
to SHP- 1 and SHP- 2, the ITIM of CEACAM1 can also 
bind Src family kinases (SFKs), which play critical signal-
ing roles in hematopoietic cell function, including activa-
tion of B cells, T cells, NK cells, monocytes, granulocytes, 
and mast cells [8]. SFKs binding to CEACAM1 are thought 
to contribute to cell adhesion properties of eosinophils 
as well as tumors [9–11]. SFK phosphorylation of 
CEACAM1 allows for CEACAM1 binding to SHP1 or 
SHP2 thus promoting inhibitory ITIM function [12]. We 
previously observed that CEACAM1 is expressed in the 
LAD3 human neoplastic mast cell line [13]. However, 
the role of CEACAM1 in the functions of mast cells or 
mast cell lines remains unknown.
Mast cells are cells of hematopoietic origin which, in 
addition to participating in innate and acquired immune 
responses, are central for the initiation of allergic reac-
tion [14]. The growth factor receptor with inherent 
tyrosine kinase activity, KIT, is essential for mast cell 
growth, differentiation and survival [15], and gain of 
function mutations in KIT allow the dysregulated growth 
of mast cells associated with the myeloproliferative dis-
order, mastocytosis [16,17]. Multiple ITIM- bearing 
receptors are expressed on mast cells, and we and others 
have demonstrated that such receptors have the capacity 
to inhibit the growth of these cells [18–24]. Generally, 
these receptors mediate inhibitory signals through inter-
actions with SHP- 1, SHP- 2, or Src homology 2 domain- 
containing inositol 5- phosphatase 1 [5], resulting in the 
suppression of normal or mutated KIT signals through 
the respective downregulation of tyrosine kinase or 
phosphatidylinositol 3- kinase- mediated responses 
[18–24].
RET is another growth factor receptor, and gain- of- 
function type mutations in this receptor drives neoplastic 
change in C cells in the thyroid gland (medullary thyroid 
carcinoma [MTC]) [25]. Two of four cases of clinical 
MTCs were reported to be CEACAM1- positive [26]. The 
role of CEACAM1 in the functions of MTCs remains 
unsettled. We therefore examined the expression and func-
tion of CEACAM1 in neoplastic mast cells (mastocytosis) 
and MTCs of human origin.
Materials and Methods
Donors
At Kyoto University Hospital (Sakyo- ku, Kyoto, Japan); 
skin biopsies were performed on 19 mastocytosis patients 
and 4 nonmastocytosis patients (chronic dermatitis, non-
specific). These patients signed the “Kyoto University 
Hospital Informed Consent Form for the Non- therapeutic 
Use of Histopathological Materials”, and the signed forms 
have been uploaded into all electronic health records. All 
mastocytosis patients were diagnosed according to the 
World Health Organization criteria. The clinical charac-
teristics of these patients are summarized in Table 1.
Medullary thyroid carcinomas were diagnosed and sur-
gically resected in Kuma Hospital (Kobe, Hyogo, Japan) 
after written permission was obtained from each patient. 
The clinical characteristics of the patients are summarized 
in Table 2.







1 0 F Systemic mastocytosis Negative
2 0 M Cutaneous mastocytosis Negative
3 0 F Cutaneous mastocytosis Positive
4 0 F Cutaneous mastocytosis Positive
5 0 M Cutaneous mastocytosis Negative
6 1 M Cutaneous mastocytosis Negative
7 1 F Cutaneous mastocytosis Negative
8 2 M Cutaneous mastocytosis Negative
9 21 M Cutaneous mastocytosis Negative
10 29 M Cutaneous mastocytosis Negative
11 30 F Cutaneous mastocytosis Negative
12 39 M Cutaneous mastocytosis Negative
13 42 M Cutaneous mastocytosis Negative
14 47 F Cutaneous mastocytosis Negative
15 51 M Systemic mastocytosis Negative
16 51 F Cutaneous mastocytosis Positive
17 59 M Cutaneous mastocytosis Positive
18 63 M Systemic mastocytosis Positive
19 64 M Cutaneous mastocytosis Negative
All cases were immunohistochemically tryptase- positive.
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Cells
Human mast cells (HuMCs) were obtained from peripheral 
blood progenitor cells using the lineage- negative cells 
(CD4− / CD8− / CD11b− / CD14− / CD16− / CD19−) 
which were obtained using MicroBeads (Miltenyi Biotec., 
Auburn, CA). The cells were cultured in METHOCULT 
SFBIT H4236, containing 1.2% methylcellulose with rhSCF 
(200 ng/mL, Peprotech, Rocky Hill, NJ), rhIL- 6 (50 ng/
mL, Peprotech), and rhIL- 3 (5 ng/mL, Peprotech) [27].
The human LAD2 mastocytosis cell line was cultured 
in StemPro- 34 medium, with supplement, containing 
 L- glutamine (2 mmol/L), penicillin (100 units/mL), strep-
tomycin (100 μg/mL), and rhSCF (100 ng/mL, Peprotech) 
[28].
The HMC1.1 (expresses V560G KIT mutation) and 
HMC1.2 (expresses V560G and D816V KIT mutations) 
human mastocytosis cell lines were grown in IMDM 
medium supplemented with FBS (10%), L- glutamine 
(2 mmol/L), penicillin (100 units/mL), and streptomycin 
(100 μg/mL) [17, 29, 30].
The K562, the 293T, the HT- 29 and the Jurkat cell 
lines were purchased from American Type Culture 
Collection (ATCC, Manassas, VA), and grown in RPMI1640 
medium supplemented with FBS (10%), L- glutamine 
(2 mmol/L), penicillin (100 units/mL), and streptomycin 
(100 μg/mL). The TT cell lines were also purchased from 
ATCC, and grown in F- 12 medium supplemented with 
FBS (10%), L- glutamine (2 mmol/L), penicillin (100 units/
mL), and streptomycin (100 μg/mL).
Antibodies, cytokines, and reagents
The mouse anti- human CEACAM1 monoclonal antibody 
(Ab) GM8G5 (mouse monoclonal Ab) for flow cytometry 
and immunohistochemistry was purchased from Alexis 
Biochemicals (San Diego, CA). The anti- CEACAM1 Ab 
(D1P4T, rabbit monoclonal Ab) for western blotting or 
immunoprecipitation was purchased from Cell Signaling 
Technology (Beverly, MA). The antimast cell tryptase Ab 
(AA1, mouse monoclonal Ab) and the antiglyceraldehyde 
3- phosphate dehydrogenase (GAPDH) Ab (6C5, mouse 
monoclonal Ab) were purchased from Abcam (Cambridge, 
MA), and the anticalcitonin Ab (rabbit polyclonal Ab) 
was from DAKO Cytomation (Glostrup, Denmark). The 
antiphospho- Src (Tyr 416) Ab (rabbit polyclonal Ab), 
anti- nonphospho- Src Ab (7G9, mouse monoclonal Ab), 
antiphospho- SHP- 1 (Tyr 564) Ab (D11G5, rabbit mono-
clonal Ab), and anti- SHP- 1 Ab (C14H6, rabbit monoclonal 
Ab) were obtained from Cell Signaling Technology. Isotype 
control Abs were obtained from BD Biosciences (Bedford, 
MA). The secondary Abs were peroxidase- labeled anti- 
rabbit or anti- mouse IgG antibodies (Santa Cruz 
Biotechnology, Santa Cruz, CA).
CEACAM1- targeting shRNA lentiviral particles and 
the control particles (off- target) were purchased from 
Santa Cruz Biotechnology. The establishment of 
CEACAM1- knockdown or mock knockdown cells (off- 
target) using LAD2, HMC1.1, HMC1.2 or TT as the 
target cells was performed according to the manufac-
turer’s instructions.
The specific SFKs inhibitor PP1 and the specific SHP- 1 
inhibitor PTP Inhibitor I, were purchased from Santa 
Cruz Biotechnology. These inhibitors were resolved in 
dimethyl sulfoxide (DMSO). We used PP1 at a concen-
tration of 200 nmol/L and PTP Inhibitor I at a concen-
tration of 50 μmol/L in each experiment.
PCR
A total of 5 x 106 HuMCs and LAD2 cells were collected 
by centrifugation and processed with TRIzol (Invitrogen 
Life Technologies, Carlsbad, CA), after overnight cytokine- 
depletion. The HMC1.1, HMC1.2, TT, K562, Jurkat, 293T, 
and HT- 29 cells were similarly processed but, as these 
cells were cytokine independent, no further overnight 
starvation was performed. The mRNA was extracted using 
RNeasy Plus kit according to the manufacturer’s instruc-
tions (QIAGEN, Hilden, Germany).
Table 2. Clinical characteristics of surgical samples donors with medul-
lary thyroid carcinoma in this study.
Case
Age 
(years) Gender RET mutation
CEACAM1 
expression
1 60 F Negative Positive
2 65 M Negative Positive
3 51 F Negative Positive
4 66 F Negative Positive
5 32 F Negative Negative
6 64 F Negative Positive
7 54 F Positive (MEN) Positive
8 36 F Positive (MEN) Positive
9 26 F Positive (MEN) Positive
10 26 F Negative Positive
11 61 M Negative Positive
12 44 F Positive (sporadic) Positive
13 42 F Positive (MEN) Positive
14 66 M Negative Negative
15 64 F Negative Negative
16 38 F Negative Positive
17 9 F Positive (sporadic) Positive
18 54 F Negative Negative
19 36 M Negative Negative
20 61 F Positive (sporadic) Positive
21 77 F Negative Negative
22 80 M Negative Positive
All cases were immunohistochemically calcitonin- positive. 
MEN; multiple endocrine neoplasia syndrome.
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One μg of each sample was used in the reverse tran-
scription (SuperScript III One- Step RT- PCR System; 
Invitrogen Life Technologies). The reverse transcription- 
PCR primers for CEACAM1 were designed according to 
ref. 31 and ref. 32; FP49 (5’- GCAACAGGACCACAGTC
AAGACGA- 3’), BP59 (5’- TGGAGTGGTCCTGAGC 
TGCCG- 3’), “exon6” (5’- GGTTGCTCTGATAGCAGTA 
G- 3’), and “3’ untranslated region” (5’- AGCCTGGAGAT 
GCCTATTAG- 3’). FP49 and BP59 primers were used to 
distinguish 3L and 4L, and “exon 6” and “3’ untranslated 
region” primers were used to distinguish 3L/4L and 3S/4S. 
Complementary DNA synthesis and PCR amplification 
were performed with a DNA Engine PTC- 200 cycler (Bio- 
Rad Laboratories) programmed with the following cycles: 
cDNA synthesis; 30 min at 55°C; denaturation: 2 min at 
94°C; PCR amplification (30 cycles): 30 sec at 94°C (dena-
ture), 1 min at 60°C (anneal), 1 min at 72°C (extend); 
final extension at 10 min at 72°C.
For the real- time PCR, one μg of each sample was 
used in the reverse transcription (PrimeScript RT Master 
Mix; Takara, Ohtsu, Japan). The reverse transcription- PCR 
primers for CEACAM1- L and β- actin were designed accord-
ing to ref. [33]; CEACAM1- L- F (5’- ACCCTGTCAAGA 
GGGAGGAT- 3’), CEACAM1- L- R (5’- TGAGGGTTTGTG 
CTCTGTGA - 3’), β- actin- F (5’- TTGCCGACAGGATG 
CAGA - 3’), and β- actin- R (5’- GCCGATCCACACGGA 
GTACT- 3’). PCR amplification were performed with a 
Thermal Cycler Dice Real Time System II (Takara) using 
SYBR Premix Ex Taq, and programmed with the follow-
ing cycles: an initial denaturation; 95°C for 30 sec; PCR 
amplification (40 cycles), 5 sec at 95°C (denature), 10 sec 
at 60°C (anneal); 15 sec at 72°C (extend); followed by a 
subsequent standard dissociation protocol.
Western blotting
Cell lysates were prepared, and the proteins were separated 
by electrophoresis and probed for immuno- reactive pro-
teins as described [34].
Flow cytometry
HuMCs which were cytokine- depleted overnight and 
HMC1.2 cells were washed, fixed, and treated with RNase 
A. The cells were incubated with anti- human CEACAM1 
(GM8G5) or control Abs overnight at 4°C followed by 
anti- mouse IgG- FITC for 6 h at 4°C. The cells were then 
analyzed using a FACScan flow cytometer.
Immunostaining
Immunohistochemistry was executed as before [24]. After 
deparaffinization with xylene, tissue sections were 
rehydrated and pretreated with 0.3% hydrogen peroxide 
for 5 min. After steam heat for 40 min, anti- human 
CEACAM1 (GM8G5), antimast cell tryptase or anticalci-
tonin Abs were added overnight at 4°C, following blocking 
background staining using Protein Block (X0909, DAKO 
Cytomation). Staining was performed using the ENVISION 
kit (DAKO Cytomation) according to the manufacturer’s 
instructions. The successful CEACAM1 staining was con-
firmed by the positive staining of lymphocytes, which 
expressed CEACAM1 [35]. Mast cell tryptase- positive cells 
were judged as neoplastic or nonneoplastic mast cells, 
and calcitonin- positive cells were as medullary thyroid 
cancer cells or nonneoplastic C cells.
For immunocytochemistry, CEACAM1- knockdown or 
mock TT cells were recultured in the 8- well chamber 
slide glass, and fixed in 4% (v/v) paraformaldehyde. Anti- 
CEACAM1 Ab (GM8G5) or isotype control Ab were added 
and incubation continued for 2 h at room temperature. 
Staining was performed using the ENVISION kit.
Cell growth assay
The Cell Counting Kit- 8 (CCK- 8; Dojindo, Kumamoto, Japan) 
was used to evaluate the proliferation of the CEACAM1- 
knockdown or mock LAD2, HMC1.1, HMC1.2, and TT cells. 
The CEACAM1- knockdown or mock LAD2 cells were cultured 
overnight in cytokine- free StemPro34. The CEACAM1- 
knockdown or mock LAD2 cells were then recultured for 
22 or 46 h at a density of 2–4 × 104 cells/100 μL of StemPro34 
with 100 ng/mL rhSCF in the 96- well dish (U- bottom) again. 
The CEACAM1- knockdown or mock HMC1.1 and HMC1.2 
cells were cultured overnight in RPMI1640 + 10% FCS. The 
CEACAM1- knockdown or mock HMC1.1 and HMC1.2 cells 
were then recultured for 22 or 46 h at a density of 3–4 × 104 
cells/100 μL of RPMI- 1640 medium + 10% FCS in the 96- 
well dish (U- bottom) again. The TT cells were cultured 
overnight at a density of 5 × 104 cells/100 μL in F12 + 10% 
FCS in the 96- well dish (Flat bottom), and recultured for 
46 or 70 h after changing the new medium. In each assay, 
we added 10 μL of CCK- 8 solution for the last 2 h and 
estimated the absorbance of the cultures at 450 nm, accord-
ing to the manufacturer’s instructions.
In other experiments, the HMC1.2 cells were cultured 
overnight in RPMI1640 + 10% FCS, and recultured for 
22 h at a density of 4 × 104 cells/100 μL of RPMI1640 + 10% 
FCS with DMSO, PP1, or PTP Inhibitor I in the 96- well 
dish (U- bottom) again. The TT cells were cultured over-
night at a density of 5 × 104 cells/100 μL in F12 + 10% 
FCS in the 96- well dish (Flat bottom), and recultured for 
46 h after changing the new medium with DMSO, PP1, 
or PTP Inhibitor I. Then, we added 10 μL of CCK- 8 
solution for the last 2 h and estimated the absorbance of 
the cultures at 450 nm.
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ELISA assay for the phosphorylation status 
of SHP- 1 and SFKs
1 × 106 CEACAM1- knockdown or mock HMC1.2 and 
TT cells were cultured overnight in the 96 well U- bottom 
and Flat bottom plates, respectively. The cells were col-
lected, and resolved in 200 μL of assay buffer. One hundred 
μL of the solution was used for ELISA assay for SHP- 1 
(Assay Biotech, Sunnyvale, CA,), and another 100 μL was 
used for ELISA assay for SFKs (Cell signaling Technology) 
according to the manufacture’s protocol.
Immunoprecipitation
Immunoprecipitation analysis was performed as described pre-
viously [20]. We utilized the beads- conjugated anti- CEACAM1 
Ab (D1P4T, rabbit monoclonal Ab) for this assay.
Statistical analysis
Data were expressed as the means ± SE. Differences between 
groups were examined for statistical significance using 
Student’s t- test (Excel: Microsoft, Seattle, WA). A P < 0.05 
indicated statistical significance.
Results
Expression of CEACAM1 in neoplastic and 
nonneoplastic human mast cells
Initially, we examined the expression of CEACAM1 mRNA 
and protein in the LAD2, HMC1.1, and HMC1.2 neo-
plastic mast cell lines. Two sets of reverse transcription- 
PCR primers for CEACAM1 mRNA were designed to 
distinguish between the 3L/4L and 3S/4S isoforms (Fig. 1A) 
Figure 1. Human neoplastic mast cells express CEACAM1. (A) Primer design for reverse transcription PCR. (B) Reverse transcription PCR (representative 
bands) and real- time PCR (relative copy numbers). (C) Western blotting for the neoplastic mast cell lines. The K562 cells were used as a positive control 
and the Jurkat cells as a negative control. (D) Flow cytometry for HMC1.2 and HuMCs. (E) Reverse transcription PCR (representative bands) and real- time 
PCR (relative copy numbers). (F) Western blotting for HuMCs. Arrowheads indicate the expected size of CEACAM1 protein. (G) Immunostaining of skin 
mastocytosis cells derived from a patient with mastocytosis or chronic dermatitis, nonspecific. Both mastocytosis cells and nonneoplastic mast cells were 
shown as tryptase- positive cells (red arrowheads), and the corresponding cells are also indicated by the red arrowheads in the right column. Bars: 50 μm.
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[31, 32]. K562 cells were used as a positive control for 
CEACAM1- 3L/4L, and HT- 29 cells were used for 
CEACAM1- 3S/4S [36, 37]. Jurkat cells were used as a 
negative control for CEACAM1- 3L/4L or 3S/4S [38]. As 
expected, mRNA for CEACAM1 was found in the K562 
and the HT- 29 cells, but not in the Jurkat cells (Fig. 1B). 
CEACAM1 mRNA was also detected in the LAD2, HMC1.1, 
and HMC1.2 human mast cell lines, with the sizes cor-
responding to the 3L/4L isoforms (Fig. 1B). Real- time 
PCR confirmed that LAD2, HMC1.1, and HMC1.2 
expressed CEACAM1- L mRNA equal to or as much as 
the level of K562 (Fig. 1B). CEACAM1- S mRNA could 
not be detected in LAD2, HMC1.1, and HMC1.2 cells 
by reverse transcription PCR (Fig. 1B). To confirm the 
presence of CEACAM1 protein, we next examined protein 
expression by immunoblot analysis. Two bands were 
detected in the lanes associated with the K562, LAD2, 
HMC1.1, and HMC1.2 cell lines (Fig. 1C). Two bands 
were observed in these cells lines, but not the Jurkat cell 
line, consistent with the appropriate molecular weights 
of CEACAM1. Flow cytometry analysis showed that 
HMC1.2 expressed the CEACAM1 on the cell surface 
(Fig. 1D). These studies confirm expression of CEACAM1 
in neoplastic mast cell lines that primarily express the 
CEACAM1- L cytoplasmic tail based upon RT- PCR.
To further examine whether or not CEACAM1 was 
expressed in primary cultured human mast cells, HuMCs 
were developed from peripheral blood progenitors of mul-
tiple donors, following which mRNA levels for CEACAM1 
were examined by reverse transcription- PCR and real- time 
PCR. In these studies, mRNA for CEACAM1 was detect-
ably in HMC1.2 cells as a positive control and nondetect-
able in 293T cells as negative control with variable detection 
in the HuMC lines (Fig. 1E). The expression levels of 
CEACAM1 protein were also variable in these cells and 
where in general very low and less than that observed in 
the HMC1.2 cell line (band at the level of arrowheads in 
Fig. 1F). Although a band was detected in the 293T cells 
and in HuMC lines 4 and 5, this band was viewed as 
nonspecific as it migrated below the positive control asso-
ciated with the HMC1.2 cell line and consistent with the 
mRNA studies. Even in the HuMC line which expressed 
CEACAM1 most strongly, the expression of CEACAM1 
could not be detectable by flow cytometry and was thus 
not detectable on the cell surface (Fig. 1D). From these 
data we conclude that although the primary cultured human 
mast cells can variably express CEACAM1 mRNA and low 
levels of protein they do not express detectable levels of 
CEACAM1 protein on the cell surface.
We next evaluated neoplastic mast cells derived from 
the mastocytosis patients. CEACAM1 expression on mast 
cells in the skin biopsies of mastocytosis patients was 
evaluated by immunohistochemical staining (Table 1). 
Neoplastic mast cells (mastocytosis) were distinguished 
by their morphology and tryptase- positivity. Five of 19 
cases (26.3%) stained positive with anti- CEACAM1 anti-
body and representative photos are shown in Figure 1G. 
In contrast, all nonneoplastic mast cells identified in the 
nonmastocytosis specimens (4 cases) were negative for 
CEACAM1 by this method (Fig. 1G).
Expression of CEACAM1 in human medullary 
thyroid carcinoma cells
Subsequently, we explored other tumor cell lines harboring 
gain- of- function type mutations in tyrosine kinases, and found 
the expression of CEACAM1 mRNA and protein in a human 
medullary thyroid carcinoma (MTC) cell line, TT. As was 
the case for HMC1.2 cells, CEACAM1 mRNA for 3L/4L 
was also detected in the TT cells by reverse transcription- 
PCR and real- time PCR (Fig. 2A). We examined protein 
expression by immunoblot analysis and immunocytochem-
istry. These studies revealed that indeed CEACAM1 protein 
was expressed in TT cells (Fig. 2B and C).
We next evaluated human MTC cells using the patho-
logical specimens resected surgically. CEACAM1 expression 
on human MTC cells in the pathological specimens was 
evaluated by immunohistochemical staining (Table 2). 
Sixteen of 22 cases (72.7%) stained positive with anti- 
CEACAM1 Ab and representative cases are shown in 
Figure 2D. The nonneoplastic C cells, from which MTCs 
are thought to arise, were also positive for CEACAM1 
from the patients with MTCs, though the C cells were 
CEACAM1- negative in the patients with benign lesions, 
such as adenomatous goiter (Fig. 2D).
CEACAM1 knockdown enhances the cell 
growth and the cell adhesion of LAD2, 
HMC1.1, and HMC1.2 cells, but suppresses 
the cell growth of TT cells
Following the determination that the human neoplastic 
mast lines LAD2, HMC1.1, and HMC1.2 and the MTC 
line TT exhibited significant expression of ITIM- containing 
CEACAM1 isoforms, we next investigated the potential 
functional role for CEACAM1 in these cells. For this 
purpose, we utilized a knockdown method using shRNA 
and established CEACAM1- knockdown LAD2, HMC1.1, 
HMC1.2 or TT cells (Fig. 3A).
We evaluated the effects of CEACAM1 knockdown on 
cell growth. We assessed the cell growth by the CCK- 8 
assay. Growth of HMC1.2 cells, which is presumably KIT- 
driven [17, 29, 30], was upregulated by the CEACAM1 
knockdown when the cells were cultured in the U- bottom 
wells for 24 or 48 h, though interestingly not in flat- 
bottom wells, suggesting that cell- cell contact was required 
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for the inhibitory effect of CEACAM1 and its reversal on 
growth upon knockdown (Fig. 3B). Cell death is a contrary 
process to cell growth. The proportions of cell death were 
almost at equal levels between CEACAM- knockdown and 
mock LAD2, HMC1.1, and HMC1.2 cells (data not shown). 
In contrast, growth of TT cells, which is presumably driven 
by mutated RET [25], was significantly downregulated by 
the CEACAM1- knockdown in the either U- bottom or flat- 
bottom wells for 48 or 72 h (Fig. 3B). The proportion 
of cell death was not significantly different between mock 
and CEACAM1- knockdown TT cells (data not shown).
CEACAM1 knockdown downregulates the 
phosphorylation of SHP- 1 in HMC1.2 cells, 
and does that of SFKs in TT cells
The inhibitory effect of CEACAM1 is mediated by the 
activation of SHP- 1 after its binding to the phosphoryl-
ated cytoplasmic tail of CEACAM1 resulting in the down-
regulation of critical tyrosine kinase- mediated signaling 
events in lymphoid cells [1]. SFKs on the other hand are 
typically activating and bind to multiple intracellular recep-
tors including CEACAM1 which, in the case, results in 
CEACAM1 phosphorylation [9]. We therefore examined 
the status of SHP- 1 and SFKs in relationship with 
CEACAM1 knockdown. We observed decreased SHP- 1 
phosphorylation, suggesting decreased activation as a con-
sequence of diminished CEACAM1 availability, but 
unchanged SFK phosphorylation upon CEACAM1- 
knockdown in HMC1.2 cells in comparison to that observed 
in mock HMC1.2 cells (Fig. 4A and B). This suggests 
that in the absence of CEACAM1, there is unopposed 
activation of SFK in HMC1.2 cells.
In contrast, upon knockdown of CEACAM1 in TT cells, 
SHP- 1 phosphorylation was similar to that observed in 
mock TT cells and SFK phosphorylation was decreased 
(Fig. 4A and B). We could not detect any difference in 
the quantity of total SFKs and SHP- 1 (Fig. 4A), and in 
the status of SHP- 2 when comparing CEACAM1- 
knockdown or mock HMC1.2 or TT cells (data not shown). 
This suggests that in TT cells, CEACAM1 is primarily 
engaged by SFK rather than SHP- 1.
Immunoprecipitaion with anti- CEACAM1 Ab (D1P4T) 
showed that CEACAM1 interacted with SHP- 1 and SFKs 
in both HMC1.2 and TT cells (Fig. 4C). However, the 
quantity of phospho- SHP- 1 which was observed to interact 
with CEACAM1 was higher than the amount of SFKs 
which interacted with CEACAM1 in HMC1.2 cells, with 
opposite findings observed in TT cells (Fig. 4C).
We assessed the growth of HMC1.2 and TT cells by add-
ing the specific inhibitors for SFKs and SHP- 1. The admin-
istration with the specific inhibitor for SFKs PP1 decreased 
the cell growth of both cells, whereas that with the specific 
inhibitor for SHP- 1 PTP inhibitor I increased the cell growth 
of both cells (Fig. 4D). Thus, SFKs were confirmed to regulate 
cell growth of HMC1.2 and TT positively, and SHP- 1 was 
confirmed to regulate cell growth of the cells negatively.
Discussion
CEACAM1- L isoforms transduce inhibitory signals via 
ITIMs contained within the cytoplasmic tail which has 
Figure 2. Human medullary thyroid carcinoma cells express CEACAM1. Human medullary thyroid carcinoma cell line TT expresses CEACAM1. (A) 
Reverse transcription PCR (representative bands) and real- time PCR (relative copy numbers), (B) Western blotting, and (C) Immunocytochemistry were 
performed. The K562 cells were used as a positive control and the Jurkat cells as a negative control. (D) Immunostaining of clinical medullary thyroid 
carcinoma cells (Case 1 & 2) and nonneoplastic C cells (red arrowheads, Case 3). Bars: 50 μm.
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previously suggested that CEACAM1 can function as a 
tumor suppressor [1]. However, the expression of 
CEACAM1- L is associated with a poor prognosis in many 
tumor types [26, 39–43]. This discrepancy is sometimes 
explained by the involvement of CEACAM1- L in 
angiogenesis, the ability of CEACAM1- L to be associated 
with increased metastasis or tumor associated CEACAM1- L 
ligation of inhibitory receptors on tumor infiltrating lym-
phocytes [4, 41, 42]. In the latter case, CEACAM1 is 
expressed on activated T and NK cells, and regulates the 
Figure 3. CEACAM1 knockdown enhances cell growth of LAD2, HMC1.1 and HMC1.2 cells, but suppresses that of TT cells. (A) Establishment of 
CEACAM1- knockdown LAD2, HMC1.1, and HMC1.2 and TT cells. Reverse transcription PCR, real- time PCR (relative copy numbers), Western blotting, 
and morphology (LAD2, HMC1.1 and HMC1.2 cells; Papanicolaou staining, TT cells; Diff- Quik stain). (B) The CCK- 8 kit was used for the evaluation of 
the cell growth of CEACAM1- knockdown or mock LAD2, HMC1.1, HMC1.2 and TT for the indicate time (n = 3, respectively). *P < 0.05, when 
compared with the value of mock cells.
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function of these cells via homophilic binding to CEACAM1 
or heterophilic binding to T- cell immunoglobulin domain 
and mucin domain- 3 and NK gene complex group 2 
member D (NKGD2), followed by the downregulation of 
antitumor immunity [4, 44]. CEACAM1 also downregulates 
NKG2D ligand on the surface of tumor cells which poten-
tially allows them to escape from the antitumor immunity 
induced by NKG2D- expressing NK cells [45].
In this study, CEACAM1- L expressed in a MTC cell 
line (TT) enhanced cell growth in association with pref-
erential interactions with and activation of SFKs. This 
suggests that CEACAM1 association with and activation 
of SFKs may promote tumor cell growth as another expla-
nation for the divergent roles ascribed to CEACAM1 in 
malignancy. In this regard, some inhibitors for SFKs have 
been reported to be effective for the treatment of MTCs 
[46, 47], and this study revealed an inhibitor for SFKs 
PP1 suppressed the growth of TT cells. These observations 
suggest their function might be via CEACAM1- L- associated 
or mutated RET- associated SFK activation. On the other 
hand, TT cells exhibited a decreased interaction with 
phospho- SHP- 1 when compared with HMC1.2 cells, sug-
gesting that this decreased association may be related to 
the increased proliferation afforded by CEACAM1- L expres-
sion in TT cells. Interestingly, there is a report that SHP- 1 
suppresses the proliferation of TT cells when stimulated 
by somatostatin [48], and we here observed that an inhibi-
tor for SHP- 1 PTP Inhibitor I enhanced the growth of 
TT cells. In addition, SHP- 1 has been reported to interact 
with mutated RET, but not to suppress mutated RET- 
associated signals [49]. It is therefore possible that sustained 
interaction of CEACAM1- L with SFKs in TT, and poten-
tially other MCTs, may force them into an activated stated 
that promotes uncontrolled proliferation.
In contrast, mastocytosis cells behaved differently. We 
detected variable levels of mRNA for CEACAM1 in normal 
mast cells derived from the blood of multiple donors, 
consistent with previous reports [50, 51]. However, we 
observed very low levels of CEACAM1 protein in normal 
mast cells and could detect little evidence of CEACAM1 
on the cell surface of them. In contrast, we observed 
significantly higher levels of CEACAM1 on neoplastic mast 
cells, based on the greater amounts of CEACAM1 protein 
Figure 4. Activated SHP- 1 is preferentially associated with CEACAM1 in 
HMC1.2 cells, whereas activated SFKs are preferentially associated with 
CEACAM1 in TT cells. The phosphorylation status of SFKs and SHP- 1 in 
CEACAM1- knockdown and mock HMC1.2 or TT cells. Western blotting. 
Data are representative of three individual experiments. (B) ELISA for 
phospho- SHP- 1 or phospho- SFKs in HMC1.2 or TT cells. Relative values 
when the values of mock cells are 100. *P < 0.05, when compared with 
the value of mock cells. (C) The interaction of SFKs or SHP- 1 with 
CEACAM1 in HMC1.2 and TT cells. Left panel: Immunoprecipitation. 
Right panel: the average of relative values of the band intensities in the 
blots (n = 3), when the band intensities of HMC1.2 are normalized to 
100. (D) The CCK- 8 kit was used for the evaluation of the effect of the 
specific inhibitor for SFKs PP1 and the specific inhibitor for SHP- 1 PTP 
inhibitor I on the cell growth of HMC1.2 (24 h) and TT (48 h) (n = 3, 
respectively). *P < 0.05, when compared with the value of mock cells.
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detected in the HMC1.2 and LAD2 cell lines compared 
to that observed in the CD34+- derived human mast cells 
from multiple donors. The expression of high levels of 
CEACAM1 expression in the neoplastic mast cells is con-
sistent with our previous report of CEACAM1 expression 
on LAD3 cells, a sister cell line of the LAD2 cell line 
[13]. Seemingly, the expression of CEACAM1- L which 
can act as tumor suppressor in mastocytosis is contradic-
tory. We are presuming that some signals constitutively 
activated in mastocytosis would induce the expression of 
CEACAM1- L, and that the expression of CEACAM1- L 
might explain the favorable prognosis of mastocytosis [14]. 
The reason for the low expression of CEACAM1 protein 
in the nonneoplastic mast cells relative to the neoplastic 
mast cells despite detectable mRNA expression is currently 
unclear. Nevertheless, in T cells there is certainly a prec-
edent for such a disconnection between mRNA and protein 
levels. Human peripheral blood T cells stimulated with 
IL- 2 plus phytohemagglutinin for 1 day express significant 
levels of CEACAM1 mRNA, but detectable levels of 
CEACAM1 protein was not observed [52]. The difference 
in expression of CEACAM1 protein in the nonneoplastic 
versus neoplastic mast cells may thus reflect differences 
in mRNA handling or posttranslational processing of the 
protein, for example, through ubiquitination and proteo-
somal targeting rather than differences in the transcriptional 
regulation. As is the case for mastocytosis, CEACAM1 
protein expression was observed in most MTCs and C 
cells with RET mutations, but not in C cells with normal 
RET. These results might suggest that similar mechanisms 
of posttranscriptional or - translational processing of 
CEACAM1 also exist in MTCs, although we did not study 
the CEACAM1 mRNA expression levels in the MTCs 
relative to C cells (counterparts as nonneoplastic MTCs) 
in the pathological specimens.
Gain- of- function mutations in KIT have been linked 
to myeloproliferative disorders, for example, acute myeloid 
leukemia (AML) and neoplastic mast cell (mastocytosis). 
In the case of mastocytosis, the D816V mutation in the 
catalytic domain of KIT is considered a major predispos-
ing factor in the progression of disease, and approaches 
to downregulate KIT activation could be considered a 
reasonable strategy for the treatment of mastocytosis. A 
potential alternative approach to inhibiting KIT activity 
would be to engage specific ITIM- containing inhibitory 
receptors expressed on the mast cell and AML surface 
with the potential of reversing responses downstream of 
activated KIT. Indeed, a number of mast cell surface 
inhibitory receptors have been demonstrated to function 
in this capacity [18–24]. Our studies reported herein sug-
gest that CEACAM1- L, by preferentially being expressed 
on neoplastic mast cells and interacting with SHP- 1, may 
allow selective targeting of these cells providing 
applicability of this approach to the treatment of masto-
cytosis. This hypothesis seemed to be assisted by the 
observation that the administration with specific inhibitors 
for SHP- 1 PTP Inhibitor I enhanced the growth of HMC1.2 
cells. There was no difference of AKT phosphorylation 
status in between CEACAM1- KD and mock HMC1.2 (data 
not shown), therefore AKT inhibition would be necessary 
to treat mastocytosis completely in addition to CEACAM1- 
related SHP- 1 activation. We previously reported that 
CD72 inhibited the growth of HMC1.2 via SHP- 1 activa-
tion, and AKT phosphorylation status was stable even 
after CD72 stimulation- induced SHP- 1 activation [20].
The CEACAM1- SFKs complex and the CEACAM1- 
SHP- 1 complex were expected to transduce competitive 
signals in both mutated KIT- harboring and mutated RET- 
harboring cells. Both mutated KIT and mutated RET 
interact with and regulate the phoshorylation of SFKs [8, 
46, 47], and are expected to induce the formation of the 
CEACAM1- SFKs complex in the cells harboring mutated 
KIT or mutated RET. SHP- 1 also interacts with and is 
phosphorylated by both mutated KIT and mutated RET 
[48, 49, 53]. Mutated KIT- interacted SHP- 1 negatively 
regulates the signals and induce the degradation and 
regeneration of KIT in the cells harboring mutated KIT 
like HMC1.2 [53], but mutated RET- interacted SHP- 1 
does not in the cells harboring mutated RET like TT [48, 
49]. We are thinking that the difference of SHP- 1 status 
in between mutated KIT- harboring (mastocytosis) and 
mutated RET- harboring (MTC) cells would result in the 
different level of the formation of the CEACAM1- SHP- 1 
complex, and the followed different ratio of the CEACAM1- 
SFKs complex/ CEACAM1- SHP- 1 complex.
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